Last reviewed · How we verify
Meningococcal Diphtheria Toxoid Vaccine
Meningococcal Diphtheria Toxoid Vaccine is a Conjugate vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Prevention of meningococcal disease caused by Neisseria meningitidis. Also known as: Menactra®.
This vaccine stimulates the immune system to produce antibodies against meningococcal polysaccharide antigens conjugated to diphtheria toxoid, providing protection against meningococcal disease.
This vaccine stimulates the immune system to produce antibodies against meningococcal polysaccharide antigens conjugated to diphtheria toxoid, providing protection against meningococcal disease. Used for Prevention of meningococcal disease caused by Neisseria meningitidis.
At a glance
| Generic name | Meningococcal Diphtheria Toxoid Vaccine |
|---|---|
| Also known as | Menactra® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Conjugate vaccine |
| Target | Meningococcal capsular polysaccharide antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine uses a conjugate approach in which meningococcal capsular polysaccharides are chemically linked to diphtheria toxoid as a carrier protein. This conjugation enhances the immunogenicity of the polysaccharide antigens and promotes a robust T-cell dependent immune response, resulting in durable antibody production and immunological memory against Neisseria meningitidis.
Approved indications
- Prevention of meningococcal disease caused by Neisseria meningitidis
Common side effects
- Injection site pain or erythema
- Fever
- Myalgia
- Headache
Key clinical trials
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (PHASE2)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever (PHASE1, PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age (PHASE3)
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents (PHASE3)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningococcal Diphtheria Toxoid Vaccine CI brief — competitive landscape report
- Meningococcal Diphtheria Toxoid Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Meningococcal Diphtheria Toxoid Vaccine
What is Meningococcal Diphtheria Toxoid Vaccine?
How does Meningococcal Diphtheria Toxoid Vaccine work?
What is Meningococcal Diphtheria Toxoid Vaccine used for?
Who makes Meningococcal Diphtheria Toxoid Vaccine?
Is Meningococcal Diphtheria Toxoid Vaccine also known as anything else?
What drug class is Meningococcal Diphtheria Toxoid Vaccine in?
What development phase is Meningococcal Diphtheria Toxoid Vaccine in?
What are the side effects of Meningococcal Diphtheria Toxoid Vaccine?
What does Meningococcal Diphtheria Toxoid Vaccine target?
Related
- Drug class: All Conjugate vaccine drugs
- Target: All drugs targeting Meningococcal capsular polysaccharide antigens
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of meningococcal disease caused by Neisseria meningitidis
- Also known as: Menactra®
- Compare: Meningococcal Diphtheria Toxoid Vaccine vs similar drugs
- Pricing: Meningococcal Diphtheria Toxoid Vaccine cost, discount & access